3 completed, 3 recruiting, 2 not yet recruiting, 1 active not recruiting. 5 Phase 2, 4 Phase 3, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Not applicable | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Graves Orbitopathy: new trials by email Literature Review of Graves Orbitopathy trials Research Report on Graves Orbitopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy | Phase 3 | Recruiting | Sling Therapeutics, Inc. | 130 | 2026-08-04 | 2026-10-20 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Completed | Lassen Therapeutics Inc. | 41 | 2024-03-05 | 2026-03-09 |
| Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) linsitinib - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Recruiting | Sling Therapeutics, Inc. | 75 | 2023-10-11 | 2025-02-25 |
| Development of a Non-Invasive Prognostic Test for Graves Orbitopathy Schirmer's test - Graves Orbitopathy, Hyperthyroidism | Not applicable | Active not recruiting | University Hospital, Ghent | 90 | 2023-05-13 | 2026-03-16 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
| Immunological Follow-up of Patients With Basedow's Orbitopathy Graves Orbitopathy | Completed | University Hospital, Montpellier | 15 | 2020-11-01 | 2022-01-11 | |
| Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy rabbit anti-thymocyte globulin - Graves Orbitopathy | Not applicable | Unknown | Medical University of Silesia | 20 | 2020-01-01 | 2022-01-20 |
Graves Ophthalmopathy (11) · Exophthalmos (5) · Endocrine System Diseases (3) · Eye Diseases (3) · Graves Disease (3) · Hashimoto Disease (3) · Orbital Diseases (3) · Thyroid Diseases (2) · Hyperthyroidism (1)
Autoimmune Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Eye Diseases, Hereditary (11) · Genetic Diseases, Inborn (11) · Goiter (11) · Immune System Diseases (11) · Hyperthyroidism (10) · Thyroid Diseases (9) · Endocrine System Diseases (8) · Eye Diseases (8) · Graves Disease (8) · Orbital Diseases (8) · Exophthalmos (6) · Thyroiditis (3) · Thyroiditis, Autoimmune (3)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (3) · Atorvastatin (2) · Antilymphocyte Serum (1) · Methylprednisolone (1) · secukinumab (1) · tofacitinib (1)
Sling Therapeutics, Inc. (3) · Banu Aji Dibyasakti (1) · Lassen Therapeutics Inc. (1) · Medical University of Silesia (1) · Novartis Pharmaceuticals (1) · Region Skane (1) · The First Affiliated Hospital of Xiamen University (1) · University Hospital, Ghent (1) · University Hospital, Montpellier (1)
United States (4) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Indonesia (1) · Italy (1) · Poland (1) · Sweden (1)
Fangsen Xiao, MD (1) · Jerzy Chudek, Prof. (1) · Tereza Planck (1)
2023 (1)